Authors
Rolf Wachter, Patrick Haag, Tobias Uhe, Miroslav Bacak, David Petroff, Mathias Forkmann, Lars Eckardt, Thomas Gaspar, Borislav Dinov, Martin Neef, Kerstin Bode, Timm Seewöster, Sotirios Nedios, Sebastian Hilbert, Matthias Lerche, Frank Lindemann, Christian Spies, Samira Beimel, Beatriz Tose Costa Paiva, Felix Hohendanner, Verena Tscholl, Radosław Lenarczyk, Leonard Bergau, Christian Sohns, Christiane Prettin, Ulrich Laufs, Gerhard Hindricks, Nikolaos Dagres, PVI-SHAM-AF Investigators
Published in
Lancet (London, England). Aug 30, 2026. Epub Aug 30, 2026.
Abstract
Guidelines recommend catheter ablation for symptom relief in patients with atrial fibrillation. The aim of this trial was to ascertain whether catheter ablation improves atrial fibrillation-related quality of life more than a sham procedure.
PVI-SHAM-AF was a double-blind, multicentre, randomised trial conducted at nine study sites in Germany and Poland. Patients aged 18 years or older with symptomatic paroxysmal or persistent atrial fibrillation were randomly assigned in a 2:1 ratio to catheter ablation or a sham procedure using an automated online randomisation system with variable block sizes, stratified by trial site. The primary endpoint was the between-group difference in change from baseline to 6 months in the Atrial Fibrillation Effect on the Quality-of-life Questionnaire (AFEQT) summary score. The prespecified primary analysis was done in the intention-to-treat population and included all randomly assigned patients, with missing data handled by multiple imputation. This trial is registered with ClinicalTrials.gov (NCT05119231) and 12-month follow-up is ongoing.
Between Nov 12, 2021, and Nov 3, 2025, 1199 patients were invited to participate in the study and 262 patients consented and were randomly assigned: 173 patients to catheter ablation and 89 to sham. The median age was 67 years (IQR 62-73); 134 (51%) were female and 128 (49%) were male. Median follow-up was 184 days (IQR 181-191). At 6 months, the mean AFEQT summary score had increased from 61·3 (SD 20·1) to 81·1 (16·6) in the catheter ablation group and from 59·2 (19·0) to 74·9 (19·5) in the sham control group. The Hodges-Lehmann estimate of the between-group difference in change was 2·6 (95% CI -2·7 to 8·0; p=0·36). One death occurred in each group; neither was considered related to the study procedure. Serious adverse events adjudicated as related or possibly related to the study procedure occurred in ten unique patients: six patients in the catheter ablation group and four patients in the sham control group. One of these was an ischaemic stroke occurred in the sham control group.
Catheter ablation did not demonstrate superiority over a sham procedure for improving atrial fibrillation-related quality of life at 6 months.
Helios Gesundheit (Förderung Leipziger Herzmedizin).
PMID:
42669307
Bibliographic data and abstract were imported from PubMed on 31 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 44
- Comments 0